Skip to main content

Candel Therapeutics, Inc.

corporate_fare Company Profile

Candel Therapeutics, Inc.

CADL·NASDAQ·Life Sciences·CIK 0001841387

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops off-the-shelf viral immunotherapies to generate an individualized, systemic anti-tumor immune response in cancer patients. The company's engineered viruses aim to induce immunogenic cell death within the tumor microenvironment, releasing tumor neo-antigens and creating a pro-inflammatory environment at the injection site. This process is intended to lead to in-situ immunization against the injected tumor and distant metastases. Local administration is designed to achieve these effects while minimizing systemic exposure and toxicity. The immune cells induced by these therapies are believed to target specific tumor antigens, potentially improving responses in immunologically "hot" tumors and transforming non-inflamed "cold" tumors into "hot" tumors. While product candidates are administered directly into the tumor, preclinical studies and clinical trials have shown systemic immune responses, suggesting the potential for an "abscopal" effect against distal, uninjected tumors. Candel Therapeutics has established two clinical off-the-shelf viral immunotherapy platforms using genetically modified adenovirus and herpes simplex virus (HSV) constructs. Its most advanced product candidate, aglatimagene besadenovec (aglatimagene, previously CAN-2409), is an off-the-shelf adenovirus product candidate administered with the prodrug valacyclovir, which has shown promising clinical activity across various solid tumor indications.

Candel Therapeutics, Inc. (NASDAQ:CADL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for CADL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CADL spans 8-K, 10-Q, DEF 14A, SCHEDULE 13D/A.

Recent high-impact activity:

  • Shares Sink 38% After-Hours as Candel Updates Application Timing
  • Candel Q3 Loss Widens to $21.9M; Prostate Cancer BLA Slips to Mid-2027
  • Q3 Loss Nearly Doubles to $21.9M as R&D Spend Jumps; Cash Lasts Into Q2 2028
  • Candel's Aglatimagene Shows 24.5-Month Survival in NSCLC Patients Failing Immunotherapy
  • Candel's Prostate Cancer Therapy Shows Durable Immune Remodeling Two Years Post-Treatment

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$38.18M
Diluted EPS
-$0.72
Op. Cash Flow
-$38.31M
Free Cash Flow
-$38.9M
Operating Income
-$48.27M
Cash & Equivalents
$119.73M
Total Debt
$46.12M
Debt / Equity
0.89×
Shares Outstanding
54.9M sh
Source: 10-K · filed 2026-03-12 · accession 0001193125-26-103134

Short Interest & Short Volume

13.31 days to cover

FINRA reported short interest of 13,087,782 shares in CADL as of the October 30, 2026 settlement, a 2.5% increase from the prior period — about 13.3 days to cover at its recent average daily volume. On November 20, 2026, 50.6% of CADL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)13,087,782 shares as of October 30, 2026
Change vs prior period▲ 2.5%
Days to cover13.31 at avg daily volume of 983,284
Daily short volume (FINRA facilities)50.6% of 653,635 shares on November 20, 2026
5-day average short volume46.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for CADL, detected from its recent SEC filings · based on capital-structure filings through 2026-11-12.

1 recent capital raiseATM program

New $50M ATM Program Established · Prior $50M Facility Fully Exhausted

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$4.99 -0.97% today
52-week range · as of 2026-11-12 $4.35 – $14
Market cap
$395.37M
Volume
1.7M (1.2× avg)
3-mo avg 1.4M
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CADL - Latest Insights

CADL
Nov 13, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $4.99 info
Change: -$0.1191 (-2%) info
Market Cap: $395.368M info
CADL
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $4.99 info
Change: -$3.40 (-41%) info
Market Cap: $395.368M info
CADL
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $4.99 info
Change: -$3.40 (-41%) info
Market Cap: $395.368M info
CADL
Oct 01, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.40
Real-time Price: $4.99 info
Change: -$5.41 (-52%) info
Market Cap: $395.368M info
CADL
Sep 30, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.96
Real-time Price: $4.99 info
Change: -$5.97 (-54%) info
Market Cap: $395.368M info
CADL
Sep 09, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.14
Real-time Price: $4.99 info
Change: -$7.15 (-59%) info
Market Cap: $395.368M info
CADL
Aug 13, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.56
Real-time Price: $4.99 info
Change: -$5.57 (-53%) info
Market Cap: $395.368M info
CADL
Aug 13, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.56
Real-time Price: $4.99 info
Change: -$5.57 (-53%) info
Market Cap: $395.368M info
CADL
Jun 30, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $10.43
Real-time Price: $4.99 info
Change: -$5.44 (-52%) info
Market Cap: $395.368M info
CADL
Jun 02, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.80
Real-time Price: $4.99 info
Change: -$3.81 (-43%) info
Market Cap: $395.368M info
CADL
May 15, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.98
Real-time Price: $4.99 info
Change: -$3.99 (-44%) info
Market Cap: $395.368M info
CADL
May 15, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $9.02
Real-time Price: $4.99 info
Change: -$4.03 (-45%) info
Market Cap: $395.368M info
CADL
May 14, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.06
Real-time Price: $4.99 info
Change: -$4.07 (-45%) info
Market Cap: $395.368M info
CADL
May 14, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $9.00
Real-time Price: $4.99 info
Change: -$4.01 (-45%) info
Market Cap: $395.368M info
CADL
Apr 29, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $6.18
Real-time Price: $4.99 info
Change: -$1.19 (-19%) info
Market Cap: $395.368M info
CADL
Apr 29, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.30
Real-time Price: $4.99 info
Change: -$1.31 (-21%) info
Market Cap: $395.368M info
CADL
Mar 18, 2026, 4:23 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $5.05
Real-time Price: $4.99 info
Change: -$0.0601 (-1%) info
Market Cap: $395.368M info
CADL
Mar 17, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.09
Real-time Price: $4.99 info
Change: -$0.0988 (-2%) info
Market Cap: $395.368M info
CADL
Mar 12, 2026, 8:17 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $5.20
Real-time Price: $4.99 info
Change: -$0.2088 (-4%) info
Market Cap: $395.368M info
CADL
Mar 12, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $5.20
Real-time Price: $4.99 info
Change: -$0.2088 (-4%) info
Market Cap: $395.368M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets